Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: The TREAT study

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 986-992

  Kreuter, M ^a,q   Vansteenkiste, J ^b   Fischer, J R ^c   Eberhardt, W ^d   Zabeck, H ^a   Kollmeier, J ^e   Serke, M ^f   Frickhofen, N ^g   Reck, M ^h   Engel Riedel, W ⁱ   Neumann, S ^j   Thomeer, M ^k   Schumann, C ^l   De Leyn, P ^b   Graeter, T ^m   Stamatis, G ⁿ   Zuna, I ^o   Griesinger, F ^p   Thomas, M ^a,q  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b University of Ziekenhuizen Leuven   (Belgium)

^c Oncology   (Belgium)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^f LUNGENKLINIK HEMER   (Germany)

^g DR HORST SCHMIDT KLINIKEN   (Germany)

^h KRANKENHAUS GROSSHANSDORF   (Germany)

ⁱ Abteilung für Pädiatrische Onkologie   (Germany)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k DEPARTMENT OF CARDIOLOGY   (Belgium)

^l UNIVERSITY HOSPITAL ULM   (Germany)

^m Klinik Loewenstein   (Germany)

ⁿ RUHRLANDKLINIK   (Germany)

^o German Center for Lung Research ^*  (Germany)

^p PIUS HOSPITAL   (Germany)

^q German Center for Lung Research   (Germany)

more..

Author keywords

Adjuvant chemotherapy; Clinical feasibility; Dose delivery; Non small cell lung cancer; Pemetrexed; Toxicity

Indexed keywords

CISPLATIN; NAVELBINE; PEMETREXED;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; KIDNEY DISEASE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORIMOTOR DISTURBANCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TINNITUS; VERTIGO;

EID: 84875577574     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds578     Document Type: Article

References (38)

1. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86: 1867-1876.
2. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
3. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
4. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with nonsmall cell lung cancer. The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-182.
5. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
6. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
7. Strauss GM, Herndon JE, 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051.
8. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two metaanalyses of individual patient data. Lancet 2010; 375: 1267-1277.
9. Douillard JY, Tribodet H, Aubert D et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer. subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010; 5: 220-228.
10. Alam N, Shepherd FA, Winton T et al. Compliance with postoperative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup Trial JBR10 and review of the literature. Lung Cancer 2005; 47: 385-394.
11. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
12. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11: 690-696.
13. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11: 435-440.
14. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
15. Kreuter M, Vansteenkiste J, Griesinger F et al. Trial on refinement of early stage non-small cell lung cancer. adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer 2007; 7: 77.
16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
17. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov (31 March 2003, date last accessed).
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
19. Jang RW, Maître AL, Ding K et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial. J Clin Oncol 2009; 27: 4268-4273.
20. Bezjak A, Lee CW, Ding K et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008; 26: 5052-5059.
21. Asmis TR, Ding K, Seymour L et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008; 26: 54-59.
22. Schmid-Bindert G, Chemaissani A, Fischer JR et al. Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC. J Clin Oncol 2009; 27: 15s, [abstract 7565].
23. Karapanagiotou EM, Boura PG, Papamichalis G et al. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res 2009; 29: 4297-4301.
24. Meyer RM, Hryniuk WM, Goodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 339-347.
25. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
26. Luciani A, Bertuzzi C, Ascione G et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2009; 66: 94-96.
27. Brunetto AT, Carden CP, Myerson J et al. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy. J Thorac Oncol 2010; 5: 1397-1403.
28. Di Maio M, Gridelli C, Gallo C et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomized trials. Lancet Oncol 2005; 6: 669-677.
29. 2 (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC [abstract]. J Thorac Oncol 2011; 6, 001.03.
30. Arriagada R, Dunant A, Pignon JP et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2009; 28: 35-42.
31. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003; 63: 1565-1577.
32. Fossa SD. Long-term sequelae after cancer therapy: survivorship after treatments for testicular cancer. Acta Oncol 2004; 43: 134-141.
33. Fossa SD, Gilbert E, Dores GM et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99: 533-544.
34. Takezawa K, Okamoto I, Okamoto W et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011; 104: 1594-1601.
35. Zheng Z, Li X, Schell MJ et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008; 112: 2765-2773.
36. Bennouna J, Senellart H, Hiret S et al. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) and cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 2011; 74: 30-34.
37. Goss GD, Lorimer I, Tsao MS et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010; 28: 18s (suppl; abstr LBA7005).
38. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.